{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-003985","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-06-20T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.582307+00:00","generated_at":"2026-05-19T02:18:27.335599+00:00","sec_items":["7.01","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Aptose enters $8.5M loan agreement with Hanmi for tuspetinib AML development","bullets":["Loan agreement with Hanmi for up to US$8.5M uncommitted facility to fund continued clinical development of tuspetinib.","Loan is a related-party transaction; Aptose relies on 'financial hardship' exemption from formal valuation and minority shareholder approval.","Tuspetinib is an oral agent targeting SYK, FLT3, KIT, JAK1/2, RSK2; ongoing TUSCANY Phase 1/2 trial in newly diagnosed AML with azacitidine and venetoclax.","Early data from first two dose cohorts showed safety, CRs, and MRD negativity across diverse mutations."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-003985","json":"https://secwatch.observer/filing/0001171843-25-003985.json","markdown":"https://secwatch.observer/filing/0001171843-25-003985.md","text":"https://secwatch.observer/filing/0001171843-25-003985.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/0001171843-25-003985-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325003985/f8k_062025.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-19T02:18:27.335599+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}